Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amrubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 0.57 |
| ▸ | THRB | P10828 | 9/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.57 |
| ▸ | BLM | P54132 | 8/20 | 0.57 |
| ▸ | RECQL | P46063 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.57 |
| ▸ | S100A4 | P26447 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | USP2 | O75604 | 4/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amrubicin SCHEMBL13091911 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL10079225 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL6254801 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL10061868 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL10080133 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL9140 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL119022 | 1.00 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL491010 | 0.99 | CHRM1 (0.98) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL2524979 | 0.99 | CHRM1 (0.98) | CHRM1TBXA2RPTGS1ADRA1AMEN1 | |
| Amrubicin SCHEMBL23909356 | 0.97 | CHRM1 (0.95) | CHRM1TBXA2RPTGS1ADRA1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139658-B2 | Medicament for treatment cancer | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-8785406-B2 | Stabilized and lyophilized formulation of anthracycline compounds | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8445653-B2 | Freeze-dried preparation of stabilized anthracycline compound | DAINIPPON SUMITOMO PHARMA (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8287918-B2 | Medicament for treating lung cancer | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120077768-A1 | STABILIZED AND LYOPHILIZED FORMULATION OF ANTHRACYCLINE COMPOUNDS | Daninippon Sumitomo Pharma Co., Ltd (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20110053879-A1 | PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER | PONIARD PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110021452-A1 | LYOPHILIZED PREPARATION OF STABILIZED ANTHRACYCLINE COMPOUNDS | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2249644-A2 | PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER | Poniard Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100092579-A1 | MEDICAMENT FOR TREATING LUNG CANCER | DAINIPPON SUMITOMO PHARMA (JP) | 2010-04-15 | — | — | US | disclosed |
| US-7659257-B2 | Medicament for treating lung cancer | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7449181-B2 | Remedies for cancer | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2008-11-11 | — | — | US | disclosed |
| EP-1308168-B1 | NOVEL REMEDIES FOR CANCER | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-20080031881-A1 | MEDICAMENT FOR TREATING CANCER | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-02-07 | — | — | US | disclosed |
| US-7091189-B2 | Medicament for treating lung cancer | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2006-08-15 | — | — | US | disclosed |
| US-20060003949-A1 | Freeze-dried preparation of stabilized anthracycline compound | SUMITOMO PHARMACEUTICALS CO. LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1570849-A1 | FREEZE-DRIED PREPARATION OF STABILIZED ANTHRACYCLINE COMPOUND | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20050119196-A1 | Remedies for lung cancer | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20040038913-A1 | Remedies for lung cancer | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| US-20030157097-A1 | Combination therapy of an anti epidermal growth factor antibody with amrubicin | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1308168-A1 | NOVEL REMEDIES FOR CANCER | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077768-A1 | STABILIZED AND LYOPHILIZED FORMULATION OF ANTHRACYCLINE COMPOUNDS | MAN1B1, TREH, MAN2B1 | TOP2A 76/4885CHRM1 4556/4885TBXA2R 4672/4885 |
| US-20060003949-A1 | Freeze-dried preparation of stabilized anthracycline compound | MGMT, BCL6, FAU | TOP2A 15/4885CHRM1 4775/4885TBXA2R 4494/4885 |
| US-20040038913-A1 | Remedies for lung cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MUC1, CD44 | TOP2A 26/4885CHRM1 3971/4885TBXA2R 3136/4885 |
| US-20110021452-A1 | LYOPHILIZED PREPARATION OF STABILIZED ANTHRACYCLINE COMPOUNDS | MGMT, ALB, MRPL21 | TOP2A 45/4885CHRM1 4522/4885TBXA2R 4334/4885 |
| US-20050119196-A1 | Remedies for lung cancer | KRAS, TOP2A, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TOP2A 2/4885CHRM1 4381/4885TBXA2R 3421/4885 |
| US-20110053879-A1 | PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER | ABCC1, SGTA, PCBP1 | TOP2A 12/4885CHRM1 3926/4885TBXA2R 3811/4885 |
| US-20100092579-A1 | MEDICAMENT FOR TREATING LUNG CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, STMN1, FOLH1 | TOP2A 54/4885CHRM1 4340/4885TBXA2R 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.